Jan. 08, 2018Topics
On the pharmaceutical side, super-dimensioned M&A activity was somewhat more modest. Many of the deals were between players in the biochemicals segment or conventional drugmakers who wanted to enter the sector.
The chemical production sector saw more activity than pharmaceuticals in 2017. Beyond the mega-mergers, one of the most significant deals of 2017 was BASF’s announcement in early December that it had signed a letter of intent with ...
Mergers and acquisitions, new petrochemical projects, the dismantling of US environmental regulations, and a tussle over the hazards of pesticides in Europe, along with a protracted discussion over life after Brexit and a few changes in ...
Dec. 04, 2017News & Opinions
Kåre Schultz, new chief executive officer of debt-plagued Israeli drugmaker Teva, is moving rapidly to make good on his pledge to improve the company’s financial performance and reposition it operationally.
Nov. 28, 2017Topics
The German capital region is one of the leading life sciences and healthcare industries centers in the world. A total of around 30,000 employees work in more than 500 companies in the pharma, the biotech and the medtech industry.
Nov. 16, 2017News & Opinions
French drugmaker Sanofi has signed an agreement to develop Principia Biopharma’s experimental oral treatment that is seen to show promise in treating multiple sclerosis (MS) and potentially other central nervous system (CNS) diseases.
Nov. 07, 2017News & Opinions
Sanofi is pursuing another US competitor for alleged breach of the patent for its top-selling diabetes drug insulin glargine (branded as Lantus and Lantus SoloStar), which together generate sales revenue of €7 billion annually. Its ...
Oct. 26, 2017News & Opinions
US drugs giant Pfizer is poised to kick off the long awaited sale of its $3.4 billion consumer health unit next month, news agencies speculate.
Oct. 11, 2017News & Opinions
Swiss specialty chemicals company Lonza has acquired Shire’s clinical-stage mammalian manufacturing site in Hayward, California, USA, boosting its cGMP capacity and supplementing existing assets in Slough, UK. Financial details of ...
Sep. 08, 2017News & Opinions
Following all regulatory approvals, French drugmaker Sanofi has completed the acquisition of Protein Sciences, a US vaccines biotech based in Meriden, Connecticut. The deal enhances the presence of Sanofi’s global vaccines global ...
The latest information directly via newsletter.